Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Holding ASND?
Track your performance easily
Earnings Data
Report Date
Apr 02, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.35Last Year’s EPS
-$2.3Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: 9.74%
|Next Earnings Date:Apr 02, 2025
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with strong progress in product development and market positioning, especially for SKYTROFA and YORVIPATH. The collaboration with Novo Nordisk highlights growth potential, while financial metrics indicate robust health. However, challenges remain, including revenue adjustments for SKYTROFA and uncertainties in the NATPARA transition.Company Guidance
During the Ascendis Pharma Q3 2024 earnings call, the company provided numerous metrics and updates that highlight its strategic progress and financial performance. SKYTROFA, Ascendis' once-weekly growth hormone product, achieved a 60% year-over-year increase in demand volume for the third quarter, maintaining a net value per patient of approximately three times that of daily growth hormone. The company anticipates full-year revenues for SKYTROFA, excluding prior year sales deductions, to reach between EUR 200 million and EUR 220 million. YORVIPATH, approved for treating adult hypoparathyroidism, is poised for a U.S. launch with estimated market potential involving 70,000 to 90,000 adults in the country. Outside the U.S., YORVIPATH has already reached 600 patients in Germany and Austria. Additionally, Ascendis plans to submit an NDA for TransCon CNP for achondroplasia in early 2025, aiming to leverage pivotal trial results showing significant growth and other important endpoints. The company also announced a collaboration with Novo Nordisk for a once-monthly GLP-1 targeting obesity and type 2 diabetes, with an upfront payment of USD 100 million and potential development milestones and royalties. Financially, Ascendis reported total revenues of EUR 57.8 million for Q3 2024, with a significant cash reserve of EUR 626 million, positioning them well for their strategic initiatives.SKYTROFA Market Position
SKYTROFA achieved a leading position in the U.S. growth hormone market with a 60% year-over-year increase in demand volume in Q3. The product maintains a net value per patient of 3x that of daily growth hormone.
YORVIPATH Launch Preparedness
Ascendis is preparing for the U.S. launch of YORVIPATH, the first FDA-approved treatment for hypoparathyroidism in adults, with a commercial infrastructure 3x the size of SKYTROFA's. The launch is expected to support 200 existing patients and will expand to all adults with chronic hypoparathyroidism by January 2025.
Novo Nordisk Collaboration
Ascendis entered a collaboration with Novo Nordisk for a once-monthly GLP-1 program targeting obesity and type 2 diabetes, expected to be a major market opportunity. The collaboration will include a $100 million upfront payment and tiered royalties.
Financial Strength and Revenue Growth
Ascendis reported a 21% increase in SKYTROFA revenue for the first nine months of 2024, totaling EUR 138.5 million. The company improved its financial position with EUR 626 million in cash and marketable securities.
---
ASND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ASND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $124.28 | $126.51 | +1.79% |
| Sep 03, 2024 | $134.68 | $119.50 | -11.27% |
| May 02, 2024 | $141.10 | $137.20 | -2.76% |
| Feb 07, 2024 | $139.29 | $139.25 | -0.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ascendis Pharma (ASND) report earnings?
Ascendis Pharma (ASND) is schdueled to report earning on Apr 02, 2025, TBA Not Confirmed.
What is Ascendis Pharma (ASND) earnings time?
Ascendis Pharma (ASND) earnings time is at Apr 02, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASND EPS forecast?
ASND EPS forecast for the fiscal quarter 2024 (Q4) is -$1.35.
---